Editorial: Intraoperative Fluorescence Imaging and Diagnosis in Central and Peripheral Nervous System Tumors: Established Applications and Future Perspectives
- PMID: 35198454
- PMCID: PMC8858970
- DOI: 10.3389/fonc.2022.845333
Editorial: Intraoperative Fluorescence Imaging and Diagnosis in Central and Peripheral Nervous System Tumors: Established Applications and Future Perspectives
Keywords: 5-ALA; CNS tumors; ICG; PNST; confocal endomicroscopy; fluorescein; fluorescence; gliomas.
Conflict of interest statement
FA and KM-S received fees from Carl Zeiss Meditec for lectures at International Scientific Meetings. CH is a consultant for NX Development Corporation (NXDC) and Synaptive Medical. NXDC, a privately held company, markets Gleolan (5-ALA, aminolevulinic acid hydrochloride). Gleolan is an optical imaging agent approved for the visualization of malignant tissue during glioma surgery. CH is a consultant for NXDC and receives royalty payments for the sale of Gleolan, has also received speaker fees by Carl Zeiss and Leica. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Intraoperative Fluorescence Imaging and Diagnosis in Central and Peripheral Nervous System Tumors: Established Applications and Future Perspectives
Publication types
LinkOut - more resources
Full Text Sources